Milk of magnesia pill: Phillips Milk of Magnesia 311 mg chewable tablet
Milk of Magnesia Uses, Side Effects & Warnings
Save
Generic name: magnesium hydroxide [ mag-NEE-see-um-hye-DROCK-side ]
Brand names: Ex-Lax Milk of Magnesia, Milk of Magnesia, Pedia-Lax Chewable, Phillips Milk of Magnesia
Drug classes: Antacids, Laxatives
Medically reviewed by Drugs.com on Nov 11, 2022. Written by Cerner Multum.
What is Milk of Magnesia?
Magnesium is a naturally occurring mineral. Milk of Magnesia reduces stomach acid, and increases water in the intestines which may induce bowel movements.
Milk of Magnesia is used as a laxative to relieve occasional constipation.
Milk of Magnesia is also used as an antacid to relieve indigestion, sour stomach, and heartburn.
Milk of Magnesia may also be used for purposes not listed in this medication guide.
Warnings
Do not use Milk of Magnesia without a doctor’s advice if you have stomach pain, nausea, or vomiting.
Before taking this medicine
Do not use Milk of Magnesia without a doctor’s advice if you have stomach pain, nausea, or vomiting.
Ask a doctor or pharmacist if Milk of Magnesia is safe to use if:
you have kidney disease;
you are on a low-magnesium diet; or
you have a sudden change in bowel habits that has been ongoing for longer than 2 weeks.
Ask a doctor before using this medicine if you are pregnant or breastfeeding.
How should I take Milk of Magnesia?
Use exactly as directed on the label, or as prescribed by your doctor.
Measure liquid medicine carefully. Use the dosing syringe provided, or use a medicine dose-measuring device (not a kitchen spoon).
You may need to shake the oral suspension before each use.
You must chew the chewable tablet before you swallow it.
Take this medicine with a full glass (8 ounces) of water.
When taken as a laxative, Milk of Magnesia should produce a bowel movement within 30 minutes to 6 hours.
Call your doctor if the condition you are treating with Milk of Magnesia does not improve, or if it gets worse while using this medicine.
Do not use Milk of Magnesia for longer than 7 days without medical advice.
Store at room temperature away from moisture and heat.
What happens if I miss a dose?
Since Milk of Magnesia is used when needed, you may not be on a dosing schedule. Skip any missed dose if it’s almost time for your next dose. Do not use two doses at one time.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
Overdose symptoms may include severe diarrhea, muscle weakness, shortness of breath, and little or no urination.
What should I avoid while taking Milk of Magnesia?
Follow your doctor’s instructions about any restrictions on food, beverages, or activity.
Milk of Magnesia side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Milk of Magnesia may cause serious side effects.
Stop using Milk of Magnesia and call your doctor at once if you have:
severe nausea, vomiting, or diarrhea;
no bowel movement after using the medicine as a laxative;
rectal bleeding; or
worsening symptoms.
Common side effects of Milk of Magnesia may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What other drugs will affect Milk of Magnesia?
Other drugs may affect Milk of Magnesia, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Frequently asked questions
- How often can you give a 4-year-old Milk of Magnesia?
More about Milk of Magnesia (magnesium hydroxide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (45)
- Latest FDA alerts (5)
- Side effects
- Dosage information
- During pregnancy
- Support group
- Drug class: antacids
- Breastfeeding
- En español
Patient resources
Other brands
Phillips’ Milk of Magnesia, Dulcolax Milk of Magnesia, Ex-Lax Milk of Magnesia, Pedia-Lax Chewable Tablets
Related treatment guides
- Constipation
- Acne
- Indigestion
Further information
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
Copyright 1996-2023 Cerner Multum, Inc. Version: 5.01.
Milk of Magnesia (magnesium hydroxide) dosing, indications, interactions, adverse effects, and more
Dosing & Uses
AdultPediatric
Dosage Forms & Strengths
chewable tablet
- 311mg
- 400mg
suspension
- 7.75%
- 400mg/5mL
- 800mg/5mL
- 1200mg/15mL
- 2400mg/10mL
Constipation
Magnesium hydroxide (400 mg/5 mL): 30-60 mL/day PO at bedtime or in divided doses
Magnesium hydroxide (800 mg/5 mL): 15-30 mL/day PO at bedtime or in divided doses
Chewable tablet: 8 tablets/day PO at bedtime or in divided doses
Acid Indigestion
Magnesium hydroxide (400 mg/5 mL): 5-15 mL PO q4hr; no more than 4 doses per 24-hour period
Chewable tablet: 2-4 tablets PO q4hr; no more than 4 doses per 24-hour period
Dosage Forms & Strengths
chewable tablet
- 311mg
- 400mg
suspension
- 7.
75% - 400mg/5mL
- 800mg/5mL
- 1200mg/15mL
- 2400mg/10mL
75%Constipation
Suspension
- 2-6 years: 5-15 mL/day of regular-strength liquid PO at bedtime or in divided doses
- 6-12 years: 15-30 mL/day (400 mg/5 mL) or 7.5-15 mL/day (800 mg/5 mL) PO at bedtime or in divided doses
- ≥12 years: 30-60 mL/day (400 mg/5 mL) or 15-30 mL/day (800 mg/5 mL) PO at bedtime or in divided doses
Chewable tablet
- 3-6 years: 2 tablets PO once daily or in divided doses
- 6-12 years: 4 tablets PO once daily or in divided doses
- >12 years: 8 tablets PO once daily or in divided doses
Acid Indigestion
Liquid
- ≥12 years: 5-15 mL (400 mg/5 mL) PO q4hr; no more than 4 doses per 24-hour period
Chewable tablet
- ≥12 years: 2-4 tablets PO q4hr; no more than 4 doses per 24-hour period
Interactions
Interaction Checker
Enter a drug name and magnesium hydroxide
No Results
No Interactions Found
Interactions Found
Contraindicated
Serious – Use Alternative
Contraindicated (0)
Serious – Use Alternative (13)
- baloxavir marboxil
magnesium hydroxide will decrease the level or effect of baloxavir marboxil by cation binding in GI tract.
Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted. - demeclocycline
magnesium hydroxide decreases levels of demeclocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- doxycycline
magnesium hydroxide decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- eltrombopag
magnesium hydroxide decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours.
- infigratinib
magnesium hydroxide will decrease the level or effect of infigratinib by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
If use with an acid-reducing agent cannot be avoided, administer infigratinib 2 hr before and after administration of a locally-acting antacid. - minocycline
magnesium hydroxide decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- oxytetracycline
magnesium hydroxide decreases levels of oxytetracycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
- pazopanib
magnesium hydroxide will decrease the level or effect of pazopanib by increasing gastric pH. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Avoid coadministration of pazopanib with drugs that raise gastric pH; may use short-acting antacids in place of PPIs and h3 antagonists, but separate antacid and pazopanib dosing by several hours
- ponatinib
magnesium hydroxide decreases levels of ponatinib by increasing gastric pH. Applies only to oral form of both agents.
Avoid or Use Alternate Drug. - potassium phosphates, IV
magnesium hydroxide decreases effects of potassium phosphates, IV by cation binding in GI tract. Avoid or Use Alternate Drug. Magnesium decreases serum phosphate concentration by binding dietary phosphate. Use alternatives if available.
- raltegravir
magnesium hydroxide will decrease the level or effect of raltegravir by cation binding in GI tract. Avoid or Use Alternate Drug. Magnesium containing antacids reduce raltegravir plasma levels when taken within 6 hr of raltegravir dose
- sotorasib
magnesium hydroxide will decrease the level or effect of sotorasib by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. If use with an acid-reducing agent cannot be avoided, administer sotorasib 4 hr before or 10 hr after administration of a locally-acting antacid.
- tetracycline
magnesium hydroxide decreases levels of tetracycline by inhibition of GI absorption.
Applies only to oral form of both agents. Avoid or Use Alternate Drug.
Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted.
If use with an acid-reducing agent cannot be avoided, administer infigratinib 2 hr before and after administration of a locally-acting antacid.
Avoid or Use Alternate Drug.
Applies only to oral form of both agents. Avoid or Use Alternate Drug.Monitor Closely (23)
- bictegravir
magnesium hydroxide will decrease the level or effect of bictegravir by cation binding in GI tract. Modify Therapy/Monitor Closely. Bictegravir can be taken under fasting conditions 2 hr before antacids containing Al, Mg, or Ca. Routine administration of bictegravir simultaneously with, or 2 hr after, antacids containing Al, Mg, or Ca is not recommended.
- cabotegravir
magnesium hydroxide will decrease the level or effect of cabotegravir by cation binding in GI tract. Modify Therapy/Monitor Closely. Administer antacid products at least 2 hr before or 4 hr after taking oral cabotegravir.
- chloroquine
magnesium hydroxide will decrease the level or effect of chloroquine by Mechanism: inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Separate doses by at least 4 hr
- ciprofloxacin
magnesium hydroxide decreases levels of ciprofloxacin by inhibition of GI absorption.
Applies only to oral form of both agents. Use Caution/Monitor. Coadministration of ciprofloxacin with multivalent cation-containing products may reduce the bioavailability of ciprofloxacin by 90%. Administer ciprofloxacin at least 2 hours before or 6 hours after using these products. Use alternatives if available. - crizotinib
magnesium hydroxide decreases levels of crizotinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Drugs that elevate the gastric pH may decrease the solubility of crizotinib and subsequently reduce its bioavailability. However, no formal studies have been conducted. .
- deferiprone
magnesium hydroxide decreases levels of deferiprone by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Deferiprone may bind polyvalent cations (eg, iron, aluminum, and zinc), separate administration by at least 4 hr between deferiprone and other medications (eg, antacids), or supplements containing these polyvalent cations.
- deflazacort
magnesium hydroxide and deflazacort both decrease serum potassium. Use Caution/Monitor.
- dolutegravir
magnesium hydroxide will decrease the level or effect of dolutegravir by cation binding in GI tract. Use Caution/Monitor. Administer dolutegravir 2 hr before or 6 hr after taking medications containing polyvalent cations; use alternative therapy if available
- fleroxacin
magnesium hydroxide decreases levels of fleroxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- gemifloxacin
magnesium hydroxide decreases levels of gemifloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- lanthanum carbonate
lanthanum carbonate, magnesium hydroxide. cation binding in GI tract. Use Caution/Monitor. Administer antacid at least 2 hours before or after lanthanum. .
- levofloxacin
magnesium hydroxide decreases levels of levofloxacin by inhibition of GI absorption.
Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours. - moxifloxacin
magnesium hydroxide decreases levels of moxifloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- ofloxacin
magnesium hydroxide decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- omadacycline
magnesium hydroxide will decrease the level or effect of omadacycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.
- pancrelipase
magnesium hydroxide decreases effects of pancrelipase by pharmacodynamic antagonism. Use Caution/Monitor. Antacids may negate beneficial effects of enzymes.
- penicillamine
magnesium hydroxide decreases levels of penicillamine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- pexidartinib
magnesium hydroxide will decrease the level or effect of pexidartinib by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Separate pexidartinib by 2 hr before or after taking a locally-acting antacid.
- riociguat
magnesium hydroxide decreases levels of riociguat by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate administration by at least 1 hour.
- sarecycline
magnesium hydroxide will decrease the level or effect of sarecycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy.
Separate dosing of tetracyclines from these products. - sodium phosphates, IV
magnesium hydroxide decreases effects of sodium phosphates, IV by cation binding in GI tract. Modify Therapy/Monitor Closely. Magnesium decreases serum phosphate concentration by binding dietary phosphate. Use alternatives if available.
- vismodegib
magnesium hydroxide will decrease the level or effect of vismodegib by Other (see comment). Use Caution/Monitor. Drugs that increase gastric pH alter vismodegib solubility and therefore reduce bioavailability; effect on efficacy unknown
- vitamin D
vitamin D increases levels of magnesium hydroxide by Other (see comment). Use Caution/Monitor.
Comment: Vitamin D can increase serum magnesium concentrations, particularly in the presence of renal impairment. The combined use of vitamin D and magnesium-containing products should be avoided, if possible, in patients with chronic renal failure.
Applies only to oral form of both agents. Use Caution/Monitor. Coadministration of ciprofloxacin with multivalent cation-containing products may reduce the bioavailability of ciprofloxacin by 90%. Administer ciprofloxacin at least 2 hours before or 6 hours after using these products. Use alternatives if available.
Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
Separate dosing of tetracyclines from these products.Minor (41)
- amikacin
amikacin decreases levels of magnesium hydroxide by increasing renal clearance.
Minor/Significance Unknown. - amiloride
amiloride increases levels of magnesium hydroxide by decreasing renal clearance. Minor/Significance Unknown.
- amphotericin B deoxycholate
amphotericin B deoxycholate decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- bazedoxifene/conjugated estrogens
bazedoxifene/conjugated estrogens decreases levels of magnesium hydroxide by Other (see comment). Minor/Significance Unknown.
Comment: Magnesium shifted from blood to tissue storage. - bendroflumethiazide
bendroflumethiazide decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- bumetanide
bumetanide decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- calcitonin salmon
calcitonin salmon increases levels of magnesium hydroxide by decreasing renal clearance. Minor/Significance Unknown.
- chlorothiazide
chlorothiazide decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- chlorthalidone
chlorthalidone decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- conjugated estrogens
conjugated estrogens decreases levels of magnesium hydroxide by Other (see comment). Minor/Significance Unknown.
Comment: Magnesium shifted from blood to tissue storage. - conjugated estrogens, vaginal
conjugated estrogens, vaginal decreases levels of magnesium hydroxide by Other (see comment). Minor/Significance Unknown.
Comment: Magnesium shifted from blood to tissue storage. - cyclopenthiazide
cyclopenthiazide decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- dextrose
dextrose decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- dextrose (Antidote)
dextrose (Antidote) decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- digoxin
digoxin decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- doxercalciferol
doxercalciferol increases levels of magnesium hydroxide by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- drospirenone
drospirenone increases levels of magnesium hydroxide by decreasing renal clearance. Minor/Significance Unknown.
- estradiol
estradiol decreases levels of magnesium hydroxide by Other (see comment). Minor/Significance Unknown.
Comment: Magnesium shifted from blood to tissue storage. - estrogens conjugated synthetic
estrogens conjugated synthetic decreases levels of magnesium hydroxide by Other (see comment). Minor/Significance Unknown.
Comment: Magnesium shifted from blood to tissue storage. - estrogens esterified
estrogens esterified decreases levels of magnesium hydroxide by Other (see comment). Minor/Significance Unknown.
Comment: Magnesium shifted from blood to tissue storage. - estropipate
estropipate decreases levels of magnesium hydroxide by Other (see comment). Minor/Significance Unknown.
Comment: Magnesium shifted from blood to tissue storage. - ethacrynic acid
ethacrynic acid decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- furosemide
furosemide decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- gentamicin
gentamicin decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- glucagon intranasal
glucagon intranasal increases levels of magnesium hydroxide by decreasing renal clearance. Minor/Significance Unknown.
- hydrochlorothiazide
hydrochlorothiazide decreases levels of magnesium hydroxide by increasing renal clearance.
Minor/Significance Unknown. - ibandronate
magnesium hydroxide decreases levels of ibandronate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- indapamide
indapamide decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- mannitol
mannitol decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- mestranol
mestranol decreases levels of magnesium hydroxide by Other (see comment). Minor/Significance Unknown.
Comment: Magnesium shifted from blood to tissue storage. - methyclothiazide
methyclothiazide decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- metolazone
metolazone decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- neomycin PO
neomycin PO decreases levels of magnesium hydroxide by increasing renal clearance.
Minor/Significance Unknown. - nitrofurantoin
magnesium hydroxide decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- paromomycin
paromomycin decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- sodium polystyrene sulfonate
sodium polystyrene sulfonate increases levels of magnesium hydroxide by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis.
- spironolactone
spironolactone increases levels of magnesium hydroxide by decreasing renal clearance. Minor/Significance Unknown.
- streptomycin
streptomycin decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- tobramycin
tobramycin decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.
- torsemide
torsemide decreases levels of magnesium hydroxide by increasing renal clearance.
Minor/Significance Unknown. - triamterene
triamterene increases levels of magnesium hydroxide by decreasing renal clearance. Minor/Significance Unknown.
Minor/Significance Unknown.
Minor/Significance Unknown.
Minor/Significance Unknown.
Minor/Significance Unknown.Previous
Next:
Adverse Effects
Frequency Not Defined
Abdominal cramping
Diarrhea
Electrolyte imbalance
Hypotension
Muscle weakness
Respiratory depression
Previous
Next:
Warnings
Contraindications
Renal failure
Existing electrolyte imbalance
Appendicitis symptoms or acute surgical abdomen
Myocardial damage or heart block
Fecal impaction or rectal fissures
Intestinal obstruction or perforation
Undiagnosed abdominal pain
Cautions
Use with caution in renal insufficiency
Previous
Next:
Pregnancy & Lactation
Pregnancy category: A
Lactation: Use in nursing mothers appears to be safe
Pregnancy Categories
A: Generally acceptable.
Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.
Previous
Next:
Pharmacology
Mechanism of Action
Laxative: Promotes osmotic retention of fluid, which distends the colon with increased peristaltic activity and stimulates bowel evacuation
Antacid: Reacts with hydrochloric acid in stomach to form magnesium chloride
Absorption
Bioavailability: 15-30%
Onset: 0.
5-6 hr (laxative)
Elimination
Excretion: Urine (up to 30% as absorbed magnesium), feces (as unabsorbed drug)
Previous
Next:
Images
| Phillips Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Phillips Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Phillips Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Phillips Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Phillips Milk of Magnesia oral – | 311 mg chewable tablet | ||
| Phillips Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Phillips Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Phillips Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Phillips Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Milk of Magnesia oral – | 400 mg/5 mL suspension | ||
| Dulcolax (magnesium hydroxide) oral – | 400 mg/5 mL suspension | ||
| Dulcolax (magnesium hydroxide) oral – | 1,200 mg chewable tablet | ||
| Pedia-Lax (mag hydroxide) oral – | 400 mg (170 mg magnesium) chewable tablet |
Copyright © 2010 First DataBank, Inc.
Milk of Magnesia – instructions for use, doses, side effects, reviews of the drug:
0.001‰
All forms of release, dosages, registration certificates, drug manufacturers, drug characteristics
Description of the drug Milk of Magnesia (oral suspension, 415 mg/5 ml) based on the official instructions, approved by the manufacturer in 1998
Date of approval: 31.07.1998
Contents
- Active substance
- Pharmacological group
- Nosological classification (ICD-10)
- Composition and form of release
- pharmachologic effect
- pharmachologic effect
- Indications
- Contraindications
- Dosage and administration
- Side effects
- Storage conditions
- Best before date
- Reviews
Active ingredient
Magnesium hydroxide
Pharmacological group
Antacids
Laxatives
Nosological classification (ICD-10)
ICD-10 code list
- K21 Gastroesophageal reflux
- K25 Gastric ulcer
- K26 Duodenal ulcer
- K29 Gastritis and duodenitis
- K30 Dyspepsia
- K31 Other diseases of the stomach and duodenum
- K59. 0 Constipation
- R14 Flatulence and related conditions
0 ConstipationComposition and formulation
1 tablet contains magnesium hydroxide 300 mg; per pack 24 pcs.
5 ml suspension for oral administration – 415 mg; in vials of 300 ml.
Pharmacological action
Pharmacological action –
antacid , laxative .
Neutralizes free hydrochloric acid in the stomach, lowers the peptic activity of gastric juice, accelerates the motility of the stomach and intestines (without secondary hypersecretion of hydrochloric acid and metabolic alkalosis).
Neutralizes free hydrochloric acid in the stomach, reduces the peptic activity of gastric juice, accelerates the motility of the stomach and intestines (without secondary hypersecretion of hydrochloric acid and metabolic alkalosis).
Indications
Increased acidity of gastric juice, gastralgia, dyspepsia, heartburn, acute duodenitis, peptic ulcer of the stomach and duodenum, flatulence, constipation.
Contraindications
Age (for suspension – up to 3 years; for tablets – up to 6 years).
Dosage and administration
Information for healthcare professionals only.
Are you a healthcare professional?
By mouth (may be taken with milk or water).
With heartburn and other dyspeptic symptoms, 2–4 tab. or 1-2 teaspoons of suspension; children from 3 to 12 years old – 1 teaspoon of suspension, children over 6 years old can also be prescribed tablets (table 1-2).
For constipation: at bedtime 2-3 tablespoons (children under 12 years old – 1-2 teaspoons) suspension. Tablets should be chewed before swallowing, the vial with the suspension should be shaken before use.
Side effects
Not identified.
Storage conditions
In a dry place (do not freeze).
Keep out of reach of children.
Expiry date
2 years.
After opening – 6 months.
Do not use after the expiry date which is stated on the pack.
Reviews
Read all reviews and leave your own.
Information for healthcare professionals only.
Are you a healthcare professional?
💊 Composition of the drug Magnesium sulfate ✅ Application of the drug Magnesium sulfate Save Search for analogues Interaction Description of the active ingredients of the preparation Magnesium sulfate The scientific information provided is general and cannot be used to make decisions. Update date: 2022.03.28 Marketing authorization holder: IVANOVSK PHARMACEUTICAL FACTORY, OJSC ATX code: A06AD04 (Magnesium sulfate) Active substance: Ph.Eur. European Pharmacopoeia Dosage form
Release form, packaging and composition |
The cardioprotective effect is due to the expansion of the coronary arteries, a decrease in peripheral vascular resistance and platelet aggregation.
| K59.0 | Constipation |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K82.8 | Other specified diseases of the gallbladder and cystic duct (incl. dyskinesia) |
| K83.0 | Cholangitis |
| T50.9 | Other and unspecified drugs, medicaments and biological substances |
| T56.0 | Lead and its compounds |
T56. 1 | Mercury and its compounds |
| T57.0 | Arsenic and its compounds |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
Dosing schedule
The method of administration and dosing regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. Compliance of the dosage form of a particular drug with indications for use and dosing regimen should be strictly observed.
For oral use. The dose, method and regimen of application, duration of therapy is determined individually, depending on the indications, the clinical situation and the age of the patient.
Side effects
Early signs and symptoms of hypermagnesemia: bradycardia, diplopia, sudden flushing of the face, headache, dizziness, decreased blood pressure, nausea, shortness of breath, slurred speech, vomiting, asthenia.
Signs of hypermagnesemia (in order of increasing magnesium concentration in the blood serum): decreased deep tendon reflexes (2-3.5 mmol/l), prolongation of the PQ interval and expansion of the QRS complex on the ECG (2.5-5 mmol/l), loss of deep tendon reflexes (4-5 mmol/l), depression of the respiratory center (5-6.5 mmol/l), impaired conduction of the heart (7.5 mmol/l), cardiac arrest (12.5 mmol/l).
Ingestion: nausea, vomiting, diarrhea, exacerbation of inflammatory diseases of the gastrointestinal tract, electrolyte imbalance (fatigue, asthenia, confusion, arrhythmia, convulsions), flatulence, spastic abdominal pain, thirst, signs of hypermagnesemia in the presence of renal insufficiency.
Contraindications for use
Hypersensitivity to magnesium sulfate; severe chronic renal failure, appendicitis, rectal bleeding (including undiagnosed), intestinal obstruction, dehydration, hypermagnesemia; pregnancy, breastfeeding period; children’s age up to 18 years.
Precautions
Impaired cardiac conduction, heart failure, chronic renal failure.
Use in pregnancy and lactation
Oral magnesium sulfate is contraindicated during pregnancy. If necessary, use during lactation, breastfeeding should be discontinued.
Use in impaired renal function
Contraindicated in severe chronic renal failure. Take with caution orally or parenterally in chronic renal failure.
Use in children
May be used in children according to indications, in doses and dosage forms recommended according to age. It is necessary to strictly follow the instructions in the instructions for magnesium sulfate preparations on contraindications for use in children of different ages of specific dosage forms of magnesium sulfate.
Use in elderly patients
Magnesium sulfate should be used with caution in elderly patients. they have reduced kidney function.
Precautions
Use with caution in case of heart block, myocardial damage, chronic renal failure, respiratory diseases, acute inflammatory diseases of the gastrointestinal tract.
Magnesium sulfate should be used with caution in elderly patients In this category of balls, a reduced dose should usually be used, because. they have reduced kidney function.
Magnesium sulfate can be used to relieve status epilepticus (as part of complex treatment).
Causes CNS depression in case of overdose. As an antidote for an overdose of magnesium sulfate, calcium preparations are used – calcium chloride or calcium gluconate.
The use of magnesium sulfate may distort the results of radiological studies for which technetium is used.
Influence on the ability to drive vehicles and mechanisms
During the period of treatment, patients should refrain from driving vehicles and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions (risk of developing diplopia, dizziness, headache ).
Drug interactions
Magnesium sulfate enhances the effect of other drugs that depress the central nervous system.:max_bytes(150000):strip_icc()/cdn.cliqueinc.com__cache__posts__184097__i-traded-my-deodorant-for-this-little-known-brazilian-remedy-1655209-1455292769.700x0c-873041bad46646c4930c9ca9c380c03a.jpg)